A STUDY OF THE COMBINATION OF OXALIPLATIN, CAPECITABINE, AND TRASTUZUMAB WITH CHEMORADIOTHERAPY IN THE ADJUVANT SETTING IN OPERATED PARTICIPANTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 POSITIVE (HER2+) GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER: